Detection of the optimum conditions for the amplification of some regions in the multidrug resistance gene in acute myeloid leukemia patients in Iraq

• Main Authors: Amran, Syazwani Itri, Hamad, Hamad Oras Naji, Shihab, Batool Ali, Abd. Al-Hasan, Ahmed Qasim, Sulaiman, Bilal K.
• Format: Article
• Published: IOSR Journals 2018
• Subjects: Q Science (General)
• Online Access: http://eprints.utm.my/id/eprint/82130/; http://www.iosrjournals.org

A molecular study on MDR1 gene by a specific PCR is carried out for the patients of acute myelogenous leukemia before and after chemotherapy to study the possible alteration in MDR1 gene and its correlation with development of multidrug resistance for acute myelogenous leukemia patients from Iraq. Samples were collected from 57 patients who were admitted to the Hematology Department of Baghdad Teaching Hospital and were diagnosed as acute myelogenous leukemia patients from 2017 to 2018 The studied Patients are classified in to two groups, the first includes 19 patients in the stage of early diagnosis and the second group involved 23 patients in the stage of after taking the treatment in addition to a control group that include 15 healthy people. Using specific primers for the promoter region, MDR1 gene has been detected in 21.1% of 19 untreated (AML) samples, in 3 of 23 patients (13.0%) treated with chemotherapy, and in only 6 of 15 (40.0%) normal blood controls. And the region of MDR represent exon 21Using DR Primer, MDR1gene has been detected in 11 of 19 (57.9%) untreated (AML) samples, in 11 of 23 patients 47.8% treated with chemotherapy, and in only 9 of 15(60.0%) normal blood controls. Using Mdr primer, MDR1 gene has been detected in 3 of 4 (75%) untreated (AML) samples, in 5 of 8 patients (62.5%) treated with chemotherapy, and in 6 of 6 (100%) normal blood controls.